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Discussion
Dr T. Rosengart (Evanston, Ill). I congratulate the authors on
a beautiful presentation. They certainly are pioneers in the field,
together with Dick Weisel and Philippe Menasche, and really have
led a growing body of evidence suggesting some very exciting
work in the possibility of cell transplant.
I have four questions for Dr. Saito. The first question involves
the use of 5-azacytidine to drive differentiation. Your histology
very elegantly shows apparent differentiation of cell lines based
upon the localization either to scar or periscar, appearing to go to
a myocyte differentiation or a fibroblast differentiation. Based
upon these findings, do you think that additional 5-azacytidine
would be efficacious or a more prolonged predifferentiation prior
to transplant?
In contrast, there certainly are a number of studies now sug-
gesting that undifferentiated cells, bone marrow or otherwise, may
equally be efficacious in driving myocardial remodeling. Given
concerns potentially by the US Food and Drug Administration or
other regulatory agencies in going to clinical trials in terms of
mutations, potential mutations, and complications using 5-azacy-
tidine, how do you see the role of using this or other differentiating
factors?
Dr Saito. We have not seen it.
Dr Rosengart. Do you think that the azacytidine plays an
important role, or do you think that simply transplanting undiffer-
entiated cells will be as efficacious?
Dr Saito. Yes, I think so. We have never seen myotube
formation or pulsating cells in a culture dish even after treatment
with 5-azacytidine. Possibly I don’t think 5-azacytidine worked.
Therefore, we reconfirmed the importance of a microenvironment.
Dr Rosengart. The second question involves the vascular
delivery, the arterial delivery, and certainly this has advantages in
terms of global dissemination, spreading of the cells throughout
the myocardium. The concern, of course, as you have shown in
your histology, is the risk of microembolization. Have you looked
at creatine kinase levels or other evidence of myocardial injury? Is
that a potential disadvantage of this delivery technique?
Dr Saito. Yes, it is a very important point. Actually we have
never checked the creatine kinase level, but if we infused more
number of cells, the mortality was much higher. For example, if I
infused 5 million cells as a preliminary study, more than half of the
animals died immediately after cell infusion. That was I think due
to microembolization. I have never seen a creatine kinase level.
Dr Rosengart. The third question involves your echo data, and
it appears very clear that when you look at your ejection fraction
and your end-diastolic and systolic volumes that you do have what
appears to be a stabilization of geometry or compliance. When you
look at your fractional shortening data at the 8-week time point,
you appear to have an improvement in function that is not consis-
tent with your other parameters. Do you have any explanation why
these parameters appear to be different?
Dr Saito. Ejection fraction was calculated using LVEDd and
LVEDs. That was presented. But when calculated, I also don’t
understand why only at 8 weeks marrow stromal cells show, how
to say, very improved cardiac function. But basically this value,
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fractional shortening, was calculated from EDd and EDs. So I
don’t know why.
Dr Rosengart. Thank you. And my final question involves
mechanism of action. On your 8-week histology it would appear
that there are a relatively sparse number of cells. I don’t know if
you have an estimation of how many cells you actually have. As
you know, obviously the two or three major mechanisms being
considered are stabilization of compliance and angiogenesis, and
then obviously the possibility that these are actually contractile
cells. It would appear based upon your cell number that stabiliza-
tion of compliance is not an obvious mechanism; certainly angio-
genesis is a possibility, but your echo data would again suggest
that maybe this is stabilizing compliance.
Do you have any theories right now which is the more likely
explanation of why this is potentially working?
Dr Saito. That is the limitation of our study, to explain the
exact mechanism. What I can do is just speculate. As you sug-
gested, we actually found some marrow stromal cells integrated
into the vascular wall, so I think some of them participated in
angiogenesis, and obviously it had a positive impact on cardiac
function. Another thing is probably that numerous cells in the
infarcted area contributed to avoid scar thinning and chamber
dilatation. So probably improvement was obtained from a combi-
nation of those factors. I can’t say clearly.
Dr J. Chachques (Paris, France). I want to congratulate you
for this research and study. I want to point also that for this cell
therapy there are two indications: one is ischemic disease and the
other can be also idiopathic dilated cardiomyopathy. In our group
we are working on both approaches experimentally.
The goal of this cell therapy in your model is to improve the
condition of the ischemic area. If you have occlusion of the
artery that will irrigate this infarction area, the cells will not
arrive toward this area, and so the cell therapy will not be
efficient to replace the dead cells. Perhaps the best indication
for cell therapy delivered through the coronary arteries is idio-
pathic dilated cardiomyopathy. In this case you can have the
cell therapy through the whole myocardium, and I think that in
your case you don’t have cells into the infarct. Can you make a
quantitative analysis of the cells that you find into the myocar-
dium?
Dr Saito. Thank you very much for your comment and the
question. Actually we estimated the number of cells in the in-
farcted area harvested at 8 weeks after cell infusion; that was
approximately 3 million cells. That was 3 times more than that of
injury infused. At the time of cell infusion it was 2 weeks after left
coronary artery ligation, and the scar formation had not been
completed. Of course there is some ischemic area, but along with
the completion of scar formation, oxygen supply and demand level
would be stabilized. And also, although left coronary ligation was
performed permanently, the resultant myocardial infarction was
rather heterogeneous; I mean, some cells survived, some vessels
were patent, and that is why they could survive even in the middle
of the scar.
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